Very Low Birth Weight Infant Clinical Trial
— THRIVEOfficial title:
Transforming Health and Resilience Via Individualized Nutrition in Very Preterm Infants for Extrauterine Growth and Development
Human milk has several well-established benefits but does not adequately meet the increased nutritional demands of the growing preterm infant, necessitating additional nutrient supplementation in a process known as fortification. In U.S. neonatal intensive care units (NICUs), human milk is primarily supplemented using standardized fortification, in which a multicomponent fortifier is added to human milk to achieve assumed nutrient content based on standard milk reference values. However, this method does not account for the significant variability in human milk composition or in preterm infant metabolism, and up to half of all very premature infants experience poor growth and malnutrition using current nutritional practices. Poor postnatal growth has adverse implications for the developing preterm brain and long-term neurodevelopment. Recent advances allow for individualized methods of human milk fortification, including adjustable and targeted fortification. Adjustable fortification uses laboratory markers of protein metabolism (BUN level) to estimate an infant's protein requirements. In targeted fortification, a milk sample is analyzed to determine its specific macronutrient and energy content, with additional macronutrient supplementation provided as needed to achieve goal values. Emerging data suggest that both methods are safe and effective for improving growth, however information on their comparable efficacy and neurodevelopmental implications are lacking, particularly using advanced quantitative brain MRI (qMRI) techniques. Through this prospective, randomized-controlled trial, the investigators will compare the impact of individualized human milk fortification on somatic growth and neurodevelopment in preterm infants. Infants will be randomized to receive one of three nutritional interventions: standardized (control group), adjustable, or targeted human milk fortification. Infants will undergo their assigned nutritional intervention until term-equivalent age or discharge home, whichever is achieved first. Brain qMRI will be performed at term-corrected age, and neurodevelopmental follow-up will be performed through 5 years of age.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | January 2034 |
Est. primary completion date | January 2034 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 4 Weeks |
Eligibility | Inclusion Criteria: - Birth gestational age (GA) of =32 weeks - Postnatal age =4 weeks at time of enrollment - Maternal plan to provide human milk to infant, and consent to providing donor human milk if insufficient maternal milk supply - Maternal age > 18 years old Exclusion Criteria: - Formula feeding prior to 36 weeks PMA or discharge home (whichever achieved first), either secondary to parental preference or medical necessity - Dysmorphic features or congenital anomalies suggestive of a genetic syndrome, metabolic disorder, chromosomal abnormality, or congenital infection - Dysgenetic or major destructive brain lesions detected by head ultrasound before enrollment |
Country | Name | City | State |
---|---|---|---|
United States | Children's National Hospital | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Children's National Research Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Weight Gain Velocity | Weight gain velocity (grams per kilogram per day) | Study enrollment through nutritional intervention endpoint (term-equivalent age (40 weeks PMA [postmenstrual age]) or discharge home, whichever is achieved first) | |
Primary | Length Growth Velocity | Length growth velocity (centimeters per week) | Study enrollment through nutritional intervention endpoint (term-equivalent age (40 weeks PMA [postmenstrual age]) or discharge home, whichever is achieved first) | |
Primary | Head Circumference Growth Velocity | Head circumference growth velocity (centimeters per week) | Study enrollment through nutritional intervention endpoint (term-equivalent age (40 weeks PMA [postmenstrual age]) or discharge home, whichever is achieved first) | |
Primary | Total and Regional Brain Volumes | Total and regional (cortical and deep gray matter, white matter, amygdala-hippocampus, brainstem, cerebellum) brain volumes by MRI | Term-equivalent age (38 to 41 weeks postmenstrual age) | |
Primary | Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Summary scores in 13 different domains (habituation, attention, handling, self-regulation, arousal, excitability, lethargy, hypertonicity, hypotonicity, non-optimal reflex, asymmetric reflex, quality of movement, stress) | Term-equivalent age (38 to 41 weeks postmenstrual age) | |
Primary | Mullen Scales of Early Learning (MSEL) | Composite score as well as 5 subscores: gross motor, fine motor, visual reception, receptive language, and expressive language (reported as standardized t-scores, higher score indicates a better outcome, mean standardized t-score of 50 with standard deviation of 10) | 18 months corrected age | |
Primary | Mullen Scales of Early Learning (MSEL) | Composite score as well as 5 subscores: gross motor, fine motor, visual reception, receptive language, and expressive language (reported as standardized t-scores, higher score indicates a better outcome, mean standardized t-score score of 50 with standard deviation of 10) | 36 months (3 years) of age | |
Primary | Wechsler Preschool and Primary Scale of Intelligence (4th edition) (WPPSI-IV) | Five primary indices: verbal comprehension, visual spatial, working memory, fluid reasoning, and processing speed (higher score indicates better performance, score range 40 to 160) | 60 months (5 years) of age | |
Primary | Differential Abilities Scale (2nd edition)-(DAS-II) | *For children with significant delays who may be unable to reach basal scores on the WPPSI-IV
Early years core battery: verbal, nonverbal, and spatial reasoning subtests (higher score indicates better performance, score range 40-170) |
60 months (5 years) of age |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04542096 -
Real Time Evaluation of Dynamic Changes of the Lungs During Respiratory Support of VLBW Neonates Using EIT
|
||
Not yet recruiting |
NCT04041765 -
IgM-Enriched Immunoglobulin for Neonatal Sepsis
|
Phase 3 | |
Completed |
NCT01683760 -
Pharmacokinetic Study of Fluconazole in Premature Infants
|
Phase 2 | |
Completed |
NCT04282655 -
Effect of Milk Warming on the Very Low Birth Weight Infant
|
N/A | |
Active, not recruiting |
NCT05436925 -
CGM Use in Preterm Infants
|
||
Completed |
NCT01515696 -
Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants
|
Phase 4 | |
Recruiting |
NCT04497012 -
Iron Supplementation and Intestinal Health
|
Phase 4 | |
Recruiting |
NCT05308134 -
Individualized Fortification of Human Milk for Infants Born ≤ 1250 g (MaxiMoM-InForM)
|
N/A | |
Completed |
NCT03682575 -
Work of Breathing in Premature Infants at Discharge
|
||
Terminated |
NCT02987764 -
Cord Milking Impacts Neurodevelopmental Outcomes in Very Low Birth Weight Infants
|
N/A | |
Completed |
NCT05686252 -
RCT: The Effect of Held Position During Kangaroo Care on Physiological Parameters of Premature Infants
|
N/A | |
Not yet recruiting |
NCT05806684 -
Hyperbilirubinemia and Retinopathy of Prematurity in Preterm Infants: a Retrospective Study.
|
||
Completed |
NCT03916159 -
Extrauterine Placental Transfusion In Neonatal Resuscitation Of Very Low Birth Weight Infants
|
N/A | |
Not yet recruiting |
NCT04640805 -
Targeted Fortification of Pasteurized Donor Human Milk
|
N/A | |
Completed |
NCT06200324 -
Clinical Outcomes of Ready-to-Use Parenteral Nutrition in Low Birth Weight Newborns in Colombia 2017-2023
|
||
Completed |
NCT05022433 -
Comparison of the Shukla and UN-1 Formulae in the Placement of the Umbilical Venous Catheter Among Neonates
|
||
Not yet recruiting |
NCT03163212 -
Safety and Tolerability of Lactoferrin/FOS in Very Low Birth Weight Infants
|
Early Phase 1 | |
Completed |
NCT00962754 -
Fluid Balance Study in Sick Neonates
|
Phase 4 | |
Not yet recruiting |
NCT06433674 -
Enteral Zinc Supplementation in Very Low Birth Weight Infants
|
Phase 3 | |
Recruiting |
NCT05961657 -
USCOM Parameters in Preterm Infants: Reference Ranges
|